Clinical Comparison of Low-dose Rosuvastatin Plus Ezetimibe Combination Therapy and High-dose Rosuvastatin Monotherapy in Patients With Minimal to Intermediate Coronary Artery Disease Without Percutaneous Coronary Intervention

Conditions: Coronary Artery Disease; Dyslipidemias; Primary Prevention Interventions: Drug: Combination drug group of Ezetimibe 10 mg/Rosuvastatin 5 mg; Drug: Mono drug group of Rosuvastatin 20 mg Sponsors: Saint Vincent ' s Hospital, Korea Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials